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Abstract
Background: Gestational diabetes mellitus (GDM) is one type of diabetes that presents during pregnancy and significantly
increases the risk of a number of adverse consequences for the fetus and mother. The microRNAs (miRNA) have recently
been demonstrated to abundantly and stably exist in serum and to be potentially disease-specific. However, no reported
study investigates the associations between serum miRNA and GDM.
Methodology/Principal Findings: We systematically used the TaqMan Low Density Array followed by individual
quantitative reverse transcription polymerase chain reaction assays to screen miRNAs in serum collected at 16–19
gestational weeks. The expression levels of three miRNAs (miR-132, miR-29a and miR-222) were significantly decreased in
GDM women with respect to the controls in similar gestational weeks in our discovery evaluation and internal validation,
and two miRNAs (miR-29a and miR-222) were also consistently validated in two-centric external validation sample sets. In
addition, the knockdown of miR-29a could increase Insulin-induced gene 1 (Insig1) expression level and subsequently the
level of Phosphoenolpyruvate Carboxy Kinase2 (PCK2) in HepG2 cell lines.
Conclusions/Significance: Serum miRNAs are differentially expressed between GDM women and controls and could be
candidate biomarkers for predicting GDM. The utility of miR-29a, miR-222 and miR-132 as serum-based non-invasive
biomarkers warrants further evaluation and optimization.
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Introduction
Gestational diabetes mellitus (GDM), defined as any degree of
glucose intolerance at first recognition during pregnancy, is one of
the most common pregnancy complications and affects approx-
imately 3–8% of all pregnancies [1,2]. Importantly, the incidence
is increasing with the increased prevalence of obesity among
women at reproductive age [3,4,5,6]. Although the detailed
mechanism how the GDM happened remains poorly known, the
GDM could lead to various adverse outcomes on pregnant women
and their offspring, such as gestational hypertension, cesarean
delivery, preterm birth, macrosomia and hyperbilirubinemia, as
well as the predispositions to the development of metabolic
syndrome and type 2 diabetes [7].
GDM is usually diagnosed at the end of the second trimester or
early third trimester based on pregnancy physiology. As recom-
mended by the American College of Obstetricians and Gynecol-
ogists (ACOG) and the American Diabetes Association (ADA), the
serum-based screening for GDM typically begins at 24–28 weeks
of gestation; however, as many use a 2-step process, testing may
not be completed until 32 weeks [8]. This leaves little time for
intervention and management of GDM. Detection of women at
higher risk of GDM early in pregnancy is a desirable goal, because
interventions, such as diet, medication and exercise, may be
applied earlier to have a positive effect on maternal and fetal
outcomes.
MiRNAs are a class of small non-coding RNAs that function as
translational repressors involved in many important biological
processes [9,10]. Specifically, miRNAs are required for pancreatic
development and the regulation of glucose stimulated insulin
secretion [11,12,13]. Growing evidence indicates that miRNAs are
involved in the pathogenesis of diabetes and that a number of
miRNAs have been reported to be differently expressed in
pancreatic b-cells, liver, adipose tissue, and/or skeletal muscle of
animal models of type 1 or type 2 diabetes, such as miR-146a, miR-
21, miR-29a, miR-34a, miR-222, and miR-375 [14]. Recently,
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serum miRNAs attracted most attention because of their unique
merits (i.e., stable, easily to be detected, and potentially disease-
specific) [15]. Although the exact mechanism how miRNAs enter
into the serum and whether they are biologically functional or
simply biomarkers for unknown etiological factors is still a big
obsession, a recent study reported that miRNAs could be selectively
packaged into microvesicles and actively secreted [16]. Therefore,
serum miRNAs could be a potential independent predictive system
for different diseases, compared with biomarkers derived from
target tissues.
In this study, we hypothesized that serum miRNA could serve as
candidate biomarkers for predicting GDM in the relatively early
pregnancy. To address this hypothesis, we systematically screened
serum miRNAs by using the Taqman Low Density Array (TLDA)
chips followed by individual quantitative reverse transcriptase
polymerase chain reaction (qRT-PCR) assays. We also performed
internal and two-centric external validations by using individual
qRT-PCR assays. Finally, in vitro analysis of miR-29a was con-
ducted in HepG2 cell lines to investigate the potential role of miR-
29a in GDM development.
Results
The characteristics of participants are summarized in Table 1.
The cases and controls were well matched on age, BMI, gestational
week and gravidity. For the discovery and internal validation
samples, serum glucose levels were slightly higher for GDM
patients, and in all samples, only eight subjects have a serum
glucose level .7.8 mmol/L but none of them .11.0 mmol/L at
that time.
In all subjects, 73 miRNAs showed DDCT.3 (i.e. 8-fold) by the
pooled TLDA chip assay (Table S1). Based on both scientific and
applicable considerations, we selected miRNAs that had at most
35 of CT value by TLDA in both two pools for further individual
qRT-PCR confirmation. As a result, 10 miRNAs were identified
and subjected to individual qRT-PCR analyses on 48 discovery-stage
samples (Table 2). Because the expression pattern of miR-222 was
reported to be associated with hyperglycemia, we included it in
further analysis, although it did not meet the criteria (TLDA:
DDCT=2.834) [17]. In the discovery stage, the expression levels of
three miRNAs (i.e., miR-132, miR-29a, and miR-222) were
significantly different between GDM women and controls
(P=0.042, 0.032, and 0.041 for miR-132, miR-29a, and miR-
222, respectively) (Figure 1).
As shown in Table 3, the expression levels of the three miRNAs
were significantly different between cases and controls in internal
validation-stage samples (P=0.034, 0.045, and 0.016 for miR-132,
miR-29a, and miR-222, respectively), while miR-29a and miR-
222 were still significantly differently expressed in the two-centric
external validation-stage samples (Wuxi: P=0.001 and 0.017 for
miR-29a and miR-222, respectively; Changzhou: P=0.001 and
0.019 for miR-29a and miR-222, respectively) (Table 3 and
Figure 1).
We further plotted the Receiver Operating Characteristic
(ROC) curves and calculated the Area under the ROC Curve
(AUC) to assess the sensitivity and specificity of the miRNA
signature individually and in combination for GDM predicting. In
the consideration of the heterogeneity of different centers, the
AUC analysis was only performed in the samples from the
discovery and internal validation stages (from Nanjing Maternity
and Child Health Hospital of Nanjing Medical University). As a
result, for single miRNA, the AUC was 64.2%, 65.8% and 60.0%
for miR-132, miR-29a and miR-222, respectively; and the AUC
was 66.9% (sensitivity=66.7% and specificity=63.3%), when we
combined all three miRNAs. Overall, 22 (18.3%) false-positive and
20 (16.7%) false-negative subjects were found in the 120 samples
(detailed data not shown).
Because insulin-induced gene 1 (Insig1) was demonstrated as a
target gene of miR-29a, and Krapivner et al. showed that Insig1
played a role in glucose homeostasis and that the action of Insig1
was related to sterol regulatory element-binding proteins (SREBP)-
mediated regulation of the hosphoenolpyruvate Carboxy Kinase 2
(PCK2), a key enzyme in gluconeogenesis and glycolysis, we further
Table 1. Characteristics of the study population.
Variable Discovery Stage P
a Internal Validation P
a
External Validation
(Wuxi) P
a
External Validation
(Changzhou) P
a
case Control case control case control case control
Age(years) 28.7962.21 29.4661.89 0.267 29.2161.61 28.5761.80 0.074 26.8861.96 26.8862.06 1 27.9462.72 26.7561.65 0.146
BMI(kg
2/m) 21.4461.70 21.961.81 0.374 21.5061.85 21.3162.17 0.638 20.6261.25 20.7361.37 0.811 21.9561.99 22.1361.93 0.794
Gestational
Week
17.4060.70 17.1660.79 0.262 17.0960.78 17.2360.76 0.373 17.5560.92 17.5360.93 0.935 16.9560.85 17.1760.88 0.470
Serum
glucose
5.3060.90 4.7660.90 0.042 5.5261.06 4.9661.20 0.041 5.5262.09 5.3561.31 0.772 5.3161.99 5.2360.48 0.875
OGTT
2+ 17 24 14 8
3+ 71 1 2 4
4+ 010 4
Gravidity
1 14 12 0.925
b 20 20 0.351
b 10 10 0.470
b 11 11 1.000
b
27 8 8 1 3 4 6 4 5
.= 3 34 83 20 1 0
aStudent’s t test.
bFisher’s exact test.
doi:10.1371/journal.pone.0023925.t001
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expression, and subsequently altered expression of PCK2 [18,19].
As shown in Figure 2, the expression of miR-29a in HepG2 cells
was significantly decreased when transfected with anti-miR-29a
compared with that in those cells transfected with anti-miR-neg.
In addition, the expression of Insig1 protein in HepG2 cells was
increased when miR-29a was down-regulated (P,0.01), and cells
with down-regulated miR-29a also had a significantly higher level
of PCK2 mRNA expression (P,0.01).
Discussion
Numerous studies have demonstrated the associations between
GDM and both neonatal morbidity and maternal complications.
Most protocols for screening and diagnosis are initiated at 24–28
gestational weeks, and previously studies have demonstrated a
number of serum markers (e.g. sex hormone-binding globulin, the
homeostasis model assessment index and C-reactive protein)
measured in the first and early second trimesters are associated
with the later diagnosis of GDM [20,21,22,23]. The present study
firstly revealed a serum miRNA signature for predicting GDM in
the early second trimester and found that signatures of the
miRNAs (mir-29a and mir-222 and miR-132) aberrant expressed
prior to serum glucose abnormality.
Several studies had reported that human serum/plasma could
serve as a class of novel promising noninvasive biomarkers for
diseases [15,24,25,26,27]. Previously, we had used a two-stage
study to investigate the role of serum miRNAs in predicting
prognosis of nonsmall-cell lung cancer (NSCLC) and found that
expression levels of four miRNAs (miR-486, miR-30d, miR-1 and
miR-499) were significantly associated with NSCLC survival [24].
Ng et al. found that the expression levels of plasma miR-92 were
significantly elevated in colorectal cancer patients and well
distinguished from gastric cancer, inflammatory bowel disease
and normal subjects [25]. Fichtlscherer et al. reported that the
expression levels of miR-126, miR-17, miR-92a and miR-155
were significantly reduced in the plasma of coronary artery disease
patients compared with healthy controls’ [26]. Finally, plasma
miR-1 expression level was found to be significantly higher in
acute myocardial infarction (AMI) patients compared with
non-AMI subjects, and the level was dropped to normal on
discharge following medication [27].
For diabetes, Chen et al. compared the serum miRNA expres-
sion in type 2 diabetic patients with that in healthy individuals and
found that the serum miRNA profiling was significantly different
between patients and controls [15]. Recently, Zampetaki et al. used
the microarray screening and qRT-PCR methods to assess the
plasma miRNA profiling in type 2 diabetes and found that
expression levels of miR-20b, miR-21, miR-24, miR-15a, miR-
126, miR-191, miR-197, miR-223, miR-320, and miR-486 were
lower in prevalent type 2 diabetes [28]. Kong et al. found that
serum miR-29a was significantly down-regulated in type 2
diabetes susceptible individuals with normal glucose tolerance (s-
NGT) and in pre-diabetes individuals compared with type 2
diabetes patients (n-T2D), but no significantly different expression
between s-NGT and pre-diabetes individuals was observed [29].
The differences between our study and those two previous studies
are: (1) Compared to non-pregnant women, pregnant women were
typically characterized as a ‘‘diabetogenic state’’ because of the
placental hormones. The human placenta is considered an active
organ playing a role in the aggravated insulin resistance by
secreting substances such as inflammatory cytokines and adipokine
[30,31,32]. (2) We tested serum miRNAs in the early second
trimester when the subjects were not having diagnostic GDM, and
none of them have increased blood glucose .11.0 mmol/L.
As of today, we just begin to understand the complex
mechanisms that culminate into the GDM phenotype and its
complications. Insig1 was a validated target gene of miR-29a and a
blocker of proteolytic activation of SREBPs, which activated genes
regulating cholesterol and fatty acid metabolism and possibly
genes involved in glucose homeostasis because of the target gene of
SREBPs was PCK2, a key enzyme in gluconeogenesis in hepatic
cells [18,33,34,35,36,37,38,39]. Therefore, overexpression of miR-
29a causing decreased levels of Insig1 may lead to a reduced
expression of PCK2, exhibiting reduced glucose concentration
[19]. A recent study reported that high glucose could reduce the
levels of miR-29a in HK-2 cells [40]. In our study, we found that
the knockdown of miR-29a could increase Insig1 expression level
and subsequently increased the level of PCK2, which may lead to
elevation of the glucose level, and the serum miR-29a expression
Table 2. Results of 11 miRNAs in the discovery stage.
miRNA GDM No GDM DDCT
b P
c
N DCT
a mean SD median N DCT
a mean SD median
hsa-miR-1 24 6.336 4.03*10-5 3.59*10-5 2.98*10-5 24 2.781 4.92*10-5 4.67*10-5 3.37*10-5 3.894 0.463
hsa-miR-125b 24 9.248 5.95*10-5 3.25*10-5 5.55*10-5 24 4.73 7.73*10-5 3.75*10-5 7.07*10-5 4.857 0.085
hsa-miR-132 24 7.27 11.98*10-5 10.47*10-5 8.75*10-5 24 3.77 17.88*10-5 9.00*10-5 16.24*10-5 3.839 0.042
hsa-miR-29a 24 7.325 11.20*10-4 8.18*10-4 8.33*10-4 24 3.766 17.01*10-4 9.89*10-4 14.38*10-4 3.898 0.032
hsa-miR-203 24 8.197 1.80*10-5 1.15*10-5 1.44*10-5 24 4.757 2.55*10-5 1.58*10-5 2.10*10-5 3.779 0.065
hsa-miR-222 24 3.203 2.43*10-3 1.72*10-3 2.02*10-3 24 0.708 3.76*10-3 2.57*10-3 3.26*10-3 2.834 0.041
hsa-miR-378 24 8.353 10.07*10-4 5.77*10-4 9.00*10-4 24 5.214 11.17*10-4 6.86*10-4 9.82*10-4 3.478 0.550
hsa-miR-518d-3p 24 7.26 8.22*10-6 9.79*10-6 4.43*10-6 24 3.814 8.68*10-6 8.01*10-6 5.49*10-6 3.785 0.860
hsa-miR-632 24 7.348 1.68*10-4 1.05*10-4 1.44*10-4 24 4.205 2.07*10-4 1.12*10-4 1.80*10-4 3.482 0.226
hsa-miR-923 24 3.324 2.70*10-3 2.84*10-3 1.62*10-3 24 0.077 3.48*10-3 6.25*10-3 1.45*10-3 3.586 0.584
hsa-miR-99a 24 9.257 7.07*10-5 3.40*10-5 6.03*10-5 24 5.785 8.88*10-5 4.66*10-5 8.44*10-5 3.811 0.131
aTLDA results of 24 pooled samples, DCT=CTsample2CTRNU6B.
bDDCT=DCTcase2DCTcontrol2DCTCel-39 from TLDA data.
cStudent’s t test from individual assay data.
doi:10.1371/journal.pone.0023925.t002
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together, we inferred that miR-29a is a negative regulator of
serum glucose. Mir-222 is located on Xp11.3, and the up-
regulation of miR-222 may be involved in cell cycle regulation
through its control of cyclin-dependent kinase inhibitor (p27
Kip1)
expression [41]. It has been shown that miR-132 was reported
significantly differently expressed in the pancreatic islets of the GK
rats, and the up-regulated miR-132 expression could decrease
production of key proteins of the insulin exocytotic machinery and
reduce insulin secretion of the GK rats [42]. However, the
biological function of miR-222 and miR-132 in GDM was not
clear up to date. Additional investigation of the regulatory
mechanism of these miRNAs and their target mRNAs mayimprove
our understanding of the molecular pathogenesis of GDM as well as
the effectiveness in identifying potential therapeutic targets and
surveillance markers for GDM.
Major strengths of our study include the use of a multistage
study design. We collected blood samples of pregnant women at
their 16–19 gestational weeks, and GDM was diagnosed at 25–28
gestational weeks. It shed light on the possible effects of earlier
intervention and greater aggressive treatment on maternal and
fetal outcomes. Furthermore, we spiked-in cel-mir-39 to normalize
the results and conducted qRT-PCR with equal numbers of cases
and control on the same plate together with cel-mir-39. However,
some limitations also need to be addressed. First, the sample size of
the external validation was relatively small, which may present
underpowered results. Second, the expression levels of miRNAs
were slightly higher in external validation samples than in
discovery and internal validation samples that may be the
consequence of lower stored temperature, which lead to less
degradation of miRNAs. Therefore, we cannot combine external
validation results when performing predictive analyses. Third,
because the investigation of the role of miR-29a in insulin
signaling was just a replication of previous studies [18,19],
additional functional studies are needed to further investigate the
role miR-29a as well as miR-222 and miR-132 in GDM. Finally,
although we demonstrated that the serum miRNAs (miR-29a,
miR222 and miR-132) were differentially expressed between
GDM women and controls, the clinical application of these
miRNAs in predicting GDM still needs further investigation and
optimization.
Materials and Methods
Study Design and Study Population
We designed a multistage retrospective nested case-control
study to determine whether serum miRNA profiling could predict
GDM development and whether the predicting property may be
prior to the change of blood glucose. All pregnant women
provided blood samples, when they received prenatal care at 16–
19 gestational weeks. The sera were isolated within 4 hours after
collection and tested for levels of random glucose using Olympus
AU5400 analyzer (Olympus Diagnostic Systerms, Southall,
Middlesex, UK). The sera of discover and internal validation
samples were stored at 220uC, and those of external validation
were stored at 270uC. At 24–28 weeks of gestation, all
Figure 1. Expression levels of miRNAs. DS: discovery stage; IS:
internal validation stage; WX: Wuxi; CZ: Changzhou Three serum
miRNAs were quantified by qRT-PCR in patients with subsequent GDM
and matched controls (n=24, 36, 16 and 16 each for DS, IS, WX and CZ,
respectively). The Box-whisker Plot represented the relative expression
levels of miRNAs that were determined by the equation 22DCT, in
which DCT=CT sample-CT cel-39. The bottom and top of the box were
the 5th and 95th percentiles, and the band near the middle of the box
was the 50th percentile of the relative expression levels of miRNAs. Any
data beyond these whiskers were shown as points.
doi:10.1371/journal.pone.0023925.g001
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and women with an abnormal 1-h post-GCT glucose level
($7.8 mmol/L) would undergo 3-h 75-g oral glucose tolerance
test (OGTT), assessing the blood glucose levels at 0, 1, 2 and 3 h
after glucose administration. Those who had results $2 abnormal
values on OGTT in accordance with ADA guidelines were
defined as cases; while those who passed GCT and/or OGTT
were chosen as controls. To control sample heterogeneity, only
those controls matched with cases on age, body mass index (BMI)
and pregnant weeks at the time of blood collecting were included
in this study. We excluded subjects with diabetes history, multiple
gestation, other pregnancy complications, and those found to have
glucose intolerance at ,20 weeks of gestation, and BMI .26, age
.33 years, and small-for gestational-age infants.
To detect the generalizable signatures of miRNAs for the
prediction of GDM, we pooled serum samples of 24 cases (from
Nanjing Maternity and Child Health Hospital of Nanjing Medical
University, Nanjing) and 24 controls, respectively, to subject them
to TLDA chip screening in the discovery stage. Then, we
performed individual qRT-PCR for the discovery-stage samples
to further filter signals of the screened miRNAs due to
heterogeneity in the subjects, as described previously [24].
Subsequently, a two-stage validation, including an internal
validation and a two- centric external validations, was conducted
to confirm the results from the discovery stage. For internal
validation, 36 cases (again from Nanjing Maternity and Child
Health Hospital of Nanjing Medical University, Nanjing) and 36
controls were tested. The controls used for discovery and internal
validation stages were recruited at the same hospital and during
the same time period as cases between July 2008 and June 2009.
The external validation was conducted with samples from two
independent centers of Wuxi and Changzhou, respectively. In
brief, 16 cases and 16 controls from Wuxi Maternity and Child
Health Hospital were recruited in parallel between March 2008
and December 2008, and 16 cases and 16 controls were recruited
in parallel between July 2006 and June 2007 from Changzhou
Maternity and Child Health Hospital. This study was approved by
the institutional review boards of Nanjing Medical University and
the participating hospitals, and a written informed consent was
also obtained from each participant. Clinical information and
birth outcomes were collected from the obstetric electronic
medical records.
Serum preparation and RNA extraction
Five-ml venous blood was collected from each participant using
a procoagulant drying tube, when they received prenatal care at
16–19 weeks of gestation. The whole blood was separated into
serum and cellular fractions by centrifugation at 4,000 rpm for
10 min, followed by 12000 rpm for 15 min to completely remove
cell debris.
Isolation of serum total RNA was described previously with some
modifications [43]. In brief, the Trizol Reagent (Invitrogen,
Carlsbad, CA) was used for serum denaturizing and Qiagen
miRNeasy Mini kit (Qiagen, Valencia, CA) for RNA collection
and purification according to the manufacturer’s protocol. Because
there was no consensus on the use of housekeeping miRNA for the
serum qRT-PCR analysis, after the initial denaturizing step, we
routinely spiked in synthetic C.elegans miR-39 (cel-mir-39, 59-ucacc-
ggguguaaaucagcuug -39) to a final concentration of 10
24 pmol/ml
for all samples in order to control variations in RNA extraction and/
or purification procedures because of the absence of homologous
sequences in humans [44]. Furthermore, all study subjects were
recruited during the same period, stored under the same conditions
(for each center), and the samples were handled in equal volume in
each experiment step to control the potential bias.
TLDA chip assays and qRT-PCR
In the discovery stage, we used TLDA Chips (human
microRNA panel V2.0, Applied Biosystems Inc, CA, USA) to
screen differentially expressed miRNAs from the two pooled
samples. A total of 960-ml serum from each pool (24 samples) was
used. Megaplex RT reactions and pre-amplification reactions were
run according to the manufacture’s protoco, in which 75-ml 0.16
TE was added to PreAmp product, and 9 -ml diluted PreAmp
product was used to run the RT-PCR reactions by dispensing
100 ml of the PCR reaction mix into each port of the TaqMan
MicroRNA Array. The default PCR procedure was used, and the
analysis was performed by using RQ manager software (Applied
Biosystems Inc.). DCT and DDCT were calculated using the
following mathematical formula: DCT=C T sample2CT RNU6B,
DDCT=DCT case2DCT control. Finally, the DDCT was normalized
against the cel-miR-39.
Then, we used TaqMan microRNA probes (Applied Biosystems
Inc.) to perform qRT-PCR assays according to the manufacturer’s
instructions [45,46]. The probe information was shown in Table
Table 3. Expression of the identified three miRNAs in the validation stages.
Validation stage miRNAs GDM No GDM P
a
N Mean SD Median N Mean SD Median
Internal validation mir-132 36 12.15*10-5 9.36*10-5 9.85*10-5 36 21.24*10-5 23.41*10-5 13.34*10-5 0.034
mir-29a 36 11.11*10-4 8.02*10-4 7.89*10-4 36 17.06*10-4 15.54*10-4 13.67*10-4 0.045
mir-222 36 2.32*10-3 1.54*10-3 1.90*10-3 36 3.51*10-3 2.45*10-3 2.97*10-3 0.016
External validation mir-132 16 3.23*10-4 2.56*10-4 2.35*10-4 16 4.32*10-4 2.56*10-4 4.00*10-4 0.235
Wuxi mir-29a 16 19.66*10-4 9.69*10-4 17.97*10-4 16 36.74*10-4 15.85*10-4 33.35*10-4 0.001
mir-222 16 5.72*10-3 2.71*10-3 5.27*10-3 16 8.73*10-3 3.91*10-3 8.02*10-3 0.017
External validation mir-132 16 14.62*10-5 7.71*10-5 13.02*10-5 16 27.55*10-5 11.75*10-5 26.27*10-5 0.001
Changzhou mir-29a 16 11.39*10-4 5.18*10-4 10.31*10-4 16 19.61*10-4 7.16*10-4 18.44*10-4 0.001
mir-222 16 3.10*10-3 1.45*10-3 2.94*10-3 16 4.48*10-3 1.69*10-3 4.36*10-3 0.019
Expression levels were relative to CTCel-39.
aStudent’s t test.
doi:10.1371/journal.pone.0023925.t003
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PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23925Figure 2. Expression of miR-29a in HepG2 cells transfected with 100 nM anti-miR-29a, anti-miR-neg or mock to determine the knockdown
efficiency of anti-miR-29a. ** P,0.01. B. Western blots for Insig1 or tubulin using protein extracts from HepG2 cells transfected with 100 nM anti-miR-
29a or anti-miR-neg. C. Expression of PCK2 in HepG2 cells transfected with 100 nM anti-miR-29a, anti-miR-neg to determine the regulation of miR-29a
on the expression of PCK2. Data represented three independent experiments 6S.E.M. with n=3. ** P,0.01.
doi:10.1371/journal.pone.0023925.g002
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A. S2. Equal volume of samples was used in each step from serum
purification to qRT-PCR. The total RNA was reverse-transcribed
to cDNA by using a TaqMan microRNA RT Kit and stem-loop
RT primers (Applied Biosystems Inc.). RT-PCR was performed
using the TaqMan PCR kit on the ABI 7900 Real-Time PCR
System (Applied Biosystems Inc.). The reactions were initiated in a
384-well optical plate at 95uC for 5 min, followed by 40 cycles of
95uC for 15 s and 60uC for 1 min. We assigned equal number of
patients and controls on one plate and run the RT-PCR for target
miRNAs and cel-miR-39 simultaneously. All reactions, including
no-template controls, were run in triplicate. The CT values were
determined using the fixed threshold settings. The relative
expression levels of target miRNAs were determined by the
equation 2
2DCT, in which DCT=C T sample2CT cel-39.
Cell Culture
The human liver carcinoma cell line HepG2 was purchased
from the cell culture center of the Chinese Academy of Medical
Sciences (Beijing, China). Cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 1 mg/ml
glucose, 10% heat-inactivated FBS, 100 IU/ml penicillin and
100 mg/ml streptomycin (Gibco/Life Technologies, Paisley, UK)
and incubated at 37uC in a humidified incubator with 5% CO2.
Transient transfection of anti-miR miRNA inhibitors
HepG2 cells were seeded in 6-well plates at 10
5 cells/well. After
24 h, 100 nM anti-hsa-miR-29a or anti-miR-neg (Gene-pharma)
were transiently transfected into HepG2 cells by Lipofectamine
2000 (Invitrogen). Forty-eight hours after transfection, cells were
extracted to perform western blot and real-time PCR.
Quantitative RT-PCR
Quantitative RT-PCR was performed to determine the
expression level of mRNAs of the hosphoenolpyruvate Carboxy
Kinase2 (PCK2) gene. RNA from HepG2 cells was isolated with
Trizol Reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s protocol. Real-time PCR was performed with
Power SYBR Green PCR Master Mix (Applied Biosystems Inc.).
Primers 59-ACCCTGCGAGTGCTTAGTG-39 and 59-TTCTC-
AGCCTCAGTTCCATC-39 were used to amplify the PCK2 gene,
and primers 59-CAAGAGATGGCCACGGCTGCT-39 and 59-
TCCTTCTGCATCCTGTCGGCA-39 were used to amplify the
b-actin gene to normalize the expression level of PCK2. All
quantitative real-time PCR reactions were run by using the
ABI7900 Real-Time PCR System (Applied Biosystems Inc.) and
performed in triplicate. Relative expression of PCK2 was calculated
using the equation 2
2DCT in which DCT=C T PCK22CT b-actin.
Western blot analysis
The insulin-induced gene1 (Insig1) protein was analyzed by
western blot from the total cell lysate as described previously [47].
Proteins were extracted with the urea lysis buffer. Proteins (50 mg)
were fractionated by electrophoresis on 12% SDS polyacrylamide
gel and transferred onto a nitrocellulose membrane (GE
Healthcare, San Francisco, CA). The membranes were blocked
in Tris-buffered saline (TBS) containing 5% nonfat milk powder for
1 h and then incubated in polyclonal anti-Insig1 (1:500, Abcam,
Cambridge, MA, USA) and anti-b-tubulin (1:2000, Abcam, Cam-
bridge, MA) diluted in TBS/5% non-fat milk powder overnight.
The expression of b-tubulin was used as the loading control.
Membranes were washed three times (10 min each) with TBS and
then incubated for 1 h with horseradish peroxidase (HRP)-
conjugated goat anti-rabbit IgG (1:1000; Beijing ZhongShan
Biotechnology CO., Beijing). Specific proteins were detected using
an ECL kit and AlphaImager (FluorChem 5500, Alpha Innotech,
San Leandro, CA). The protein expression level was analyzed by
AlphaEaseFC software (Alpha Innotech, San Leandro, CA).
Statistical Analysis
Differences in demographic and clinical characteristics and
mean expression levels of miRNAs were evaluated by x
2 tests or
the student’s t test between GDM women and controls. To
investigate the effectiveness of the three-miRNA (miR-132, miR-
29a and miR-222) signature for GDM predicting, a risk score
analysis was constructed. The upper 25% reference interval of
each miRNA value in controls of the discovery stage was set as the
threshold to code the expression level of the corresponding
miRNA for each sample as 0 and 1 in discovery and internal
validation stages (from Nanjing Maternity and Child Health
Hospital of Nanjing Medical University). The risk score of each
miRNA was calculated using the weights by the regression
coefficient that was derived from the univariate logistic regression
analysis of each miRNA. We further assigned each patient a risk
score function according to a linear combination of the expression
level of the miRNAs. The risk score=(21.21546expression
level of miR-132)+(21.6083856expression level of miR-29a)+
(20.9295366expression level of miR-222). The AUC was
calculated for each and the combination of the three miRNAs,
respectively, in orders to assess the individual and combined effects
of the miRNAs on GDM predicting. All the statistical analyses
were performed with Stata version 9.2 (Stata Corporation, College
Station, TX, USA). A P value of less than.05 was considered
statistically significant, and all tests were two tailed.
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